Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.
Tokyo, Japan, Feb 24, 2006 - (JCN) - Takeda Pharmaceutical and its US subsidiary Takeda Pharmaceuticals North America jointly announced on February 22 that they have won a patent infringement case against Mylan, Watson and Ranbaxy.
The US District Court for the Southern District of New York ruled on February 21 that Takeda's patent covering the active ingredient of ACTOS (pioglitazone pioglitazone /pi·o·glit·a·zone/ (pi?o-glit´ah-zon) an antidiabetic agent that decreases insulin resistance in the peripheral tissues and liver; used as the hydrochloride salt in the treatment of type 2 diabetes mellitus. HCI) is valid and enforceable. Accordingly, the US Food and Drug Administration cannot approve any generic version of ACTOS until 2011, when Takeda's patent expires.
In addition, Takeda Pharmaceutical retains several patents regarding ACTOS and its use, which are valid until 2016. ACTOS is an insulin resistance reducer for type 2 diabetes.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion